Sanofi Genzyme

Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. It is engaged in the development of specialty care therapies to target a range of serious medical conditions. In addition, the company operates RegistryNXT, a web-based technology platform designed to collect patient clinical data related to the onset, progression, and treatment course of Gaucher, Fabry, MPS I, and Pompe diseases.
HQCambridge, US
Cybersecurity ratingAMore
Sanofi Genzyme was founded in 1981 and is headquartered in Cambridge, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Sanofi Genzyme

Bill Sibold

Bill Sibold

Executive Vice President and Head of Sanofi Genzyme
Manuela Buxo

Manuela Buxo

Head of Europe
Charles Castano

Charles Castano

Global Digital Head
Aimee Christian

Aimee Christian

Global Communications Head
Carole Huntsman

Carole Huntsman

Head, Sanofi Genzyme North America and U.S. Country Lead
Mark Underwood

Mark Underwood

Head of Planning and Operations
Show more

Sanofi Genzyme Office Locations

Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations
Cambridge, US (HQ)
50 Binney St
Boston, US
Copenhagen, DK
Show all (23)

Sanofi Genzyme Financials and Metrics

Summary Metrics

Founding Date


Sanofi Genzyme Revenue

Sanofi Genzyme's revenue was reported to be €10.43 b in FY, 2019 which is a 26.1% increase from the previous period.
EURFY, 2017FY, 2018FY, 2019



Revenue growth, %

Show all financial metrics

Sanofi Genzyme Operating Metrics

Sep, 2018Nov, 2020


100 100



Patents (US)



Show all operating metrics

Sanofi Genzyme Acquisitions / Subsidiaries

Company NameDateDeal Size
BioenvisionMay 29, 2007$345 m
AnorMEDOctober 17, 2006$580 m
BoneCare InternationalJuly 01, 2005$719 m
VerigenFebruary 09, 2005
ILEX Oncology, Inc.December 20, 2004$1 b
SangStatSeptember 10, 2003
BiomatrixDecember 18, 2000$738 m
PharmagenicsJune 16, 1997$28 m

Sanofi Genzyme Revenue Breakdown

Embed Graph

Sanofi Genzyme revenue breakdown by geographic segment: 20.8% from Europe, 56.9% from United States, 10.4% from Rest of the world and 11.8% from Emerging markets

Sanofi Genzyme Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Sanofi Genzyme Online and Social Media Presence

Embed Graph

Sanofi Genzyme News and Updates

Olipudase alfa demonstrated significant improvement in lung function and spleen volume in patients with ASMD

Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated significant improvement in lung function and spleen volume in patients with acid sphingomyelinase deficiency (ASMD). Results from two separate clinical trials of adult and pediatric patients were presented at th…

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

Additional positive results were announced from Part A of a pivotal Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). As previously reported, the trial met both of its co-primary and all key secondary endpoin…

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

Genetic testing and counseling through PD GENEration provides people with Parkinson's disease with detailed knowledge of their genetic status relative to key Parkinson's-related genes, ultimately empowering them to know more about their own disease. GBA, LRRK2 and SNCA are examples of genes associat…

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab), recommending to extend the approval in the European Union (EU) to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for s…

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

A pivotal Phase 3 trial of Dupixent® (dupilumab) met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. In a broad type 2 inflammatory asthma patient population, defined as having elevated eosinophils (EOS) or elevated fractional e…

AKF and Sanofi Genzyme Launch Campaign for Awareness of Fabry Disease

In a recent press release, the American Kidney Fund (AKF) announced an education and awareness campaign to increase visibility of Fabry disease. The campaign will include encouraging patients with chronic kidney disease (CKD) with an unknown underlying cause to get tested for Fabry disease. The camp…
Show more

Sanofi Genzyme Frequently Asked Questions

  • When was Sanofi Genzyme founded?

    Sanofi Genzyme was founded in 1981.

  • Who are Sanofi Genzyme key executives?

    Sanofi Genzyme's key executives are Bill Sibold, Manuela Buxo and Charles Castano.

  • How many employees does Sanofi Genzyme have?

    Sanofi Genzyme has 9,961 employees.

  • What is Sanofi Genzyme revenue?

    Latest Sanofi Genzyme annual revenue is €10.4 b.

  • What is Sanofi Genzyme revenue per employee?

    Latest Sanofi Genzyme revenue per employee is €1 m.

  • Who are Sanofi Genzyme competitors?

    Competitors of Sanofi Genzyme include Biogen, Amgen and Amicus Therapeutics.

  • Where is Sanofi Genzyme headquarters?

    Sanofi Genzyme headquarters is located at 50 Binney St, Cambridge.

  • Where are Sanofi Genzyme offices?

    Sanofi Genzyme has offices in Cambridge, Boston, Baltimore, Bridgewater Township and in 19 other locations.

  • How many offices does Sanofi Genzyme have?

    Sanofi Genzyme has 23 offices.